INSM Insmed Incorporated

$129.41▲ +1.67% Healthcare Other
After hours $129.41▲ +0.00% Sep 11, 7:56 PM ET
Volume 1.70M Avg Volume (10D) 1.96M
Key Metrics & Fundamentals
Market Cap
$28.26B
P/E Ratio
–
Div Yield
–%
52W Range
90.39 - 212.75
% vs 50 MA
10.17%
% vs 200 MA
-7.14%
RSI-14
60.3
MACD Histogram
-0.0800
Beta (1Y vs SPY)
0.53
Free Cash Flow
-$95.09M
Gross Rev
$425.49M
Gross Profit
$358.27M
EBITDA
-$98.01M
COGS
$67.21M
Operating Exp
$459.58M
Operating Income
-$101.31M
EBIT
-$101.31M
Pretax Income
-$11.37M
Net Income
-$13.24M
EPS (Diluted)
-0.06
Price & Volume History
Loading chart…
Recent News
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Zacks · Sep 11, 2026 6:21 PM
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Zacks · Sep 10, 2026 5:38 PM
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
Insider Monkey · Sep 10, 2026 11:52 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · Sep 4, 2026 11:00 AM
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
PR Newswire · Sep 3, 2026 11:00 AM
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
Insider Monkey · Sep 2, 2026 4:25 PM
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
Insider Monkey · Sep 2, 2026 8:42 AM
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Zacks · Aug 31, 2026 2:14 PM
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Zacks · Aug 27, 2026 6:22 PM
Insmed to Present at September 2026 Investor Conferences
PR Newswire · Aug 26, 2026 11:00 AM
Financial Overview - Income Statement Quarterly

See INSM's money flow as a full page

Social Sentiment
Avg +0.06 · 11 posts
NewsTradeDiscussionNasdaq 100 Profit margins before and after new inclusions
r/wallstreetbets · Jun 18, 2026
Negative margin of -144.4% indicates significant losses.
very_negative -0.80
DDNewsDiscussionPriceTarget$INSM stock pitch
r/wallstreetbets · Aug 11, 2025
The post presents a bullish argument based on FDA approval, clinical trial results, and potential market size.
positive +0.80
TradeDiscussionBiotech trading or investing is hard, but what if you follow the smart money?
r/wallstreetbets · Oct 8, 2024
INSM fits the described criteria of a mid-cap company with strong clinical assets, aligning with the author's strategy.
positive +0.50
TradeDiscussionPriceTargetThe INSM juggernaut comes to an end.
r/wallstreetbets · Jun 25, 2024
The author expresses negative sentiment about INSM, anticipating a price drop and views it as a 'rigged' market situation.
very_negative -0.80
TradePriceTargetINSM is an unstoppable juggernaut
r/wallstreetbets · Jun 18, 2024
The author describes the stock as an 'unstoppable juggernaut' and details repeated upward price jumps, indicating a bullish sentiment.
positive +0.60
Page 1 of 3 (11 total)
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙